Gland Pharma shares reached a new 52-week high after the company reported strong results for the March quarter and full year. The European unit Cenexi showed signs of recovery while new product launches and capacity additions supported the outlook.
Gland Pharma stock climbed to its highest level in a year following the release of robust quarterly and annual figures. The company highlighted improving profitability at its European subsidiary Cenexi as a key positive factor.
Laurus Labs reported strong financial results for fiscal 2026, driving a 30 percent gain in its share price. Growth in contract manufacturing and a better product mix supported the performance.
AI에 의해 보고됨
Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.
European stocks closed the week lower on Friday, with the STOXX 600 index hitting a two-week low. Investors cited concerns over growth and inflation from the ongoing Middle East conflict disrupting energy supplies. While technology shares gained, healthcare and financial sectors declined.
AI에 의해 보고됨
Nine BSE smallcap companies delivered standout performances in the March 2026 quarter, with net profits surging over 50% year-on-year and share prices rising 50% to 170% in the past year. Four of these stocks became multibaggers, more than doubling investor returns. Data from ACE Equity highlights the momentum amid mixed results from 168 reporting firms.